The SEC's enforcement programme on biotechnology's communications with the investment community

Arthur S Gabinet

DOI:https://doi.org/10.5912/jcb165

Abstract:

The proliferation of biotechnology start-up companies has led to increased scrutiny by the regulators of the securities markets. The author, a former head of a field office of the United States Securities and Exchange Commission, examines the growing cooperation among regulatory agencies in the U.S. and the basic structure of the disclosure and anti-fraud provisions of the U.S. securities laws. The author articulates the approaches that the SEC division of enforcement has taken to investigating and prosecuting violations of the securities laws by biotechnology companies and provides useful guidance for dealing with news that may impact the securities markets.

Keywords:securities ,insider trading ,fraud ,disclosure ,SEC ,en ,